Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus and long-term outcomes in renal transplantation.
Campistol JM, de Fijter JW, Nashan B, Holdaas H, Vítko S, Legendre C. Campistol JM, et al. Among authors: holdaas h. Transplantation. 2011 Aug 15;92(3 Suppl):S3-26. doi: 10.1097/TP.0b013e3182230900. Transplantation. 2011. PMID: 21799392 No abstract available.
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
Fellström B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C; Assessment of Lescol in Renal Transplantation (ALERT) study group. Fellström B, et al. Among authors: holdaas h. Clin Transplant. 2006 Nov-Dec;20(6):732-9. doi: 10.1111/j.1399-0012.2006.00555.x. Clin Transplant. 2006. PMID: 17100723 Clinical Trial.
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ; ASCERTAIN Investigators. Holdaas H, et al. Transplantation. 2011 Aug 27;92(4):410-8. doi: 10.1097/TP.0b013e318224c12d. Transplantation. 2011. PMID: 21697773 Clinical Trial.
Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.
Mjörnstedt L, Schwartz Sørensen S, von Zur Mühlen B, Jespersen B, Hansen JM, Bistrup C, Andersson H, Gustafsson B, Solbu D, Holdaas H. Mjörnstedt L, et al. Among authors: holdaas h. Transpl Int. 2015 Jan;28(1):42-51. doi: 10.1111/tri.12437. Epub 2014 Sep 30. Transpl Int. 2015. PMID: 25176389 Free article. Clinical Trial.
Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study.
Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J, van der Giet M, Murbraech K; ELEVATE Study Group. Holdaas H, et al. Transplantation. 2017 Oct;101(10):2612-2620. doi: 10.1097/TP.0000000000001739. Transplantation. 2017. PMID: 28333860 Clinical Trial.
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial.
Bredewold OW, Chan J, Svensson M, Bruchfeld A, de Fijter JW, Furuland H, Grinyo JM, Hartmann A, Holdaas H, Hellberg O, Jardine A, Mjörnstedt L, Skov K, Smerud KT, Soveri I, Sørensen SS, Zonneveld AV, Fellström B. Bredewold OW, et al. Among authors: holdaas h. Kidney Med. 2022 Nov 18;5(1):100574. doi: 10.1016/j.xkme.2022.100574. eCollection 2023 Jan. Kidney Med. 2022. PMID: 36593877 Free PMC article.
269 results